Welcome to LookChem.com Sign In|Join Free
  • or
2-(4-(Trifluoromethyl)phenyl)cyclopropanecarboxylic acid is a complex organic compound with the molecular formula C11H9F3O2. It features a cyclopropane ring, which is a three-carbon ring, and a phenyl group (C6H5) with a trifluoromethyl (CF3) substituent at the para position. The carboxylic acid group (COOH) is attached to the cyclopropane ring, making it an acidic compound. This chemical is known for its potential applications in pharmaceuticals and agrochemicals, particularly as a building block for the synthesis of various drugs and pesticides. Its unique structure, with the trifluoromethyl group providing increased lipophilicity and metabolic stability, makes it an interesting candidate for medicinal chemistry research.

2262-03-5

Post Buying Request

2262-03-5 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

2262-03-5 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 2262-03-5 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,2,6 and 2 respectively; the second part has 2 digits, 0 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 2262-03:
(6*2)+(5*2)+(4*6)+(3*2)+(2*0)+(1*3)=55
55 % 10 = 5
So 2262-03-5 is a valid CAS Registry Number.
InChI:InChI=1/C11H9F3O2/c12-11(13,14)7-3-1-6(2-4-7)8-5-9(8)10(15)16/h1-4,8-9H,5H2,(H,15,16)

2262-03-5Downstream Products

2262-03-5Relevant academic research and scientific papers

HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF

-

, (2019/05/22)

Heterocyclic compounds of Formula (I) and pharmaceutically acceptable salt thereof are disclosed. The use of such heterocyclic compounds and pharmaceutically acceptable salt thereof for the treatment of cancers, and more particularly cancers sensitive to mitochondrial activity inhibition and increased reactive oxygen species (ROS) levels, is also disclosed. Such cancers include acute myeloid leukemia (AML), preferably AML characterized by certain features, such as high level of expression of one or more Homeobox (HOX)-network genes, high and/or low expression of specific genes, the presence of one or more cytogenetic or molecular risk factors such as intermediate cytogenetic risk, Normal Karyotype (A/K), mutated NPM1, mutated CEBPA, mutated FLT3, mutated DNMT3A, mutated TET2, mutated IDH1, mutated IDH2, mutated RUNX1, mutated WT1, mutated SRSF2, intermediate cytogenetic risk with abnormal karyotype (intern(abnK)), trisomy 8 (+8) and/or abnormal chromosome (5/7), and/or a high leukemic stem cell (LSC) frequency.

METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS

-

Paragraph 0254; 0255; 0258, (2013/07/19)

Described herein are methods of treating Parkinson's disease using arylcyclopropylamine compounds.

Benzimidazole Modulators of VR1

-

Page/Page column 195, (2008/06/13)

The invention is directed to compounds of Formula (I): to pharmaceutical compositions containing such compounds and to methods of treatment using them.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 2262-03-5